Plasma Exosome miR-203a-3p is a Potential Liquid Biopsy Marker for Assessing Tumor Progression in Breast Cancer Patients
Quick Facts
- Publication title: Plasma Exosome miR-203a-3p is a Potential Liquid Biopsy Marker for Assessing Tumor Progression in Breast Cancer Patients
- Journal: Breast Cancer-Targets and Therapy
- Year: 2024
- DOI: 10.2147/BCTT.S478328
- PMID/PMCID: 39310782; PMC11416789
Research overview
Cox regression analyses and survival analyses were performed on candidate miRNAs to explore their prognostic value (n = 848). Our findings suggested that plasma exosomal miR-203a-3p could hold potential as a liquid biopsy marker for evaluating BC progression in patients.
Key findings
We found that only miR-203a-3p was progressively elevated with BC progression and was associated with poor prognosis in the TCGA dataset.
Its potential target genes were enriched in pathways related to tumor progression, and the downregulation of 48 of these genes was associated with poor prognosis.
More importantly, plasma exosomal miR-203a-3p was also found to gradually increase with BC progression, and its expression was positively correlated with miR-203a-3p in BC tissues.
This result suggests that plasma exosomal miR-203a-3p may reflect the expression of miR-203a-3p in tumor tissues and serve as a potential liquid biopsy marker for monitoring BC progressions.
Study design
In the TCGA database, we first screened for miRNAs significantly associated with BC progression by comparing miRNA expression in para-carcinoma tissues, stage I BC tissues, and stage II-III BC tissues (n = 1026).
Cox regression analyses and survival analyses were performed on candidate miRNAs to explore their prognostic value (n = 848).
KEGG, GO, and PPI analyses were used to identify enriched pathways associated with cancer.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization, miRNA profiling/sequencing and bioinformatic analysis; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Plasma Exosome miR-203a-3p is a Potential Liquid Biopsy Marker for Assessing Tumor Progression in Breast Cancer Patients Breast Cancer-Targets and Therapy. 2024. DOI: 10.2147/BCTT.S478328. PMID/PMCID: 39310782; PMC11416789.